Legal & General Group
SGTX

Legal & General Group’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Legal & General Group’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-95
Closed -$1K – 3512
2022
Q2 		$1K Hold
95
– – ﹤0.01% 3509
2022
Q1 		$2K Hold
95
– – ﹤0.01% 3557
2021
Q4 		$3K Hold
95
– – ﹤0.01% 3568
2021
Q3 		$7K Buy
95
+47
+98% +$3.62K ﹤0.01% 3471
2021
Q2 		$7K Sell
48
-12
-20% -$2.11K ﹤0.01% 3451
2021
Q1 		$17K Buy
+60
New +$23.9K ﹤0.01% 3195

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Legal & General Group's SGTX Position: Q3 2022 in Review

Legal & General Group sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2022, closing a stake of 95 shares — an estimated $1K sold.

Legal & General Group first reported a position in SGTX in Q1 2021 and held it in 6 quarters. The position peaked at $17K in Q1 2021. 33 funds tracked by Wall St. Rank hold SGTX as of Q3 2022.

  • Legal & General Group reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 95 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1K.
  • Legal & General Group first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
  • Legal & General Group's Sigilon Therapeutics, Inc. Common Stock position peaked at $17K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.